United States — Food and Drug Administration & Lewis Kahn

United States — Food and Drug Administration: The FDA published briefing documents critical of Capricor's statistical analysis plan and raised concerns about the benefit-risk profile of Deramiocel. This regulatory action triggered the stock drop and the subsequent lawsuit, and it may influence the advisory committee's decision on the BLA.

Lewis Kahn: Lewis Kahn is the Managing Partner at Kahn Swick & Foti and is the contact person for investors in the class action lawsuit. He plays a key role in soliciting investors and managing the case.

United States — Food and Drug Administration: The United States — Food and Drug Administration issued a warning letter to ImmunityBio regarding misleading efficacy claims made by Patrick Soon-Shiong about Anktiva, which triggered the stock price drop and subsequent lawsuits.

Lewis Kahn: Lewis Kahn is the Managing Partner of Kahn Swick & Foti, LLC, and is involved in reminding investors about the class action lawsuit.

United States — Food and Drug Administration: Regulator whose briefing documents and advisory committee vote triggered the stock collapse and legal actions.

Lewis Kahn: Managing partner at Kahn Swick & Foti involved in the lawsuit.

Lewis Kahn: Lewis Kahn is the Managing Partner at Kahn Swick & Foti, involved in the class action lawsuit against UniQure.